Dr. Adil Daud is the Director of Melanoma Clinical Research at the Helen Diller Family Comprehensive Cancer Center at UC San Francisco. He is an expert in immunotherapy and has pioneered the development of novel immunotherapeutics and targeted therapies. He led the development of IL-12 in melanoma and has developed a novel technology to deliver it in vivo. He has also played a major role in developing anti-PD-1 therapies in humans.; most recently, he developed novel assays to determine immune responsiveness in vivo, which can be used to determine the likelihood of response to immune therapy and provide novel insights into immune drug development. Prior to joining UCSF, Dr. Daud was a faculty member and researcher at the Moffitt Cancer Center in Tampa, FL.

Dr. Daud earned his medical degree at the Government Medical College, Nagpur. He completed an internship and a residency in internal medicine at Indiana University School of Medicine, followed by a fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center.